

2015
Press release



www.genfit.com

GENFIT ANNOUNCES ITS TURNOVER AND CASH POSITION AS OF SEPTEMBER 30, 2015

(Non-audited data established in accordance with IFRS standards)

Lille (France), Cambridge (Massachusetts, United States), November 6, 2015 – GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces its turnover for the period January 1st to September 30th, 2015 and its cash position as of September 30th, 2015.

The turnover as of September 30, 2015 amounts to €0.45 million, compared to €1.32 million for the same period in 2014. As of September 30, 2015, the cash, cash equivalents, and current financial instruments of the Company amounted to €64.32 million. The cash position as of September 30, 2014 amounted to €58.61 million.

The third quarter of 2015 was marked by the progress of the biomarkers program in NASH, the Company having developed a diagnostic tool – as an alternative to invasive liver biopsy – to identify NASH patients that should be treated, according to the consensual definition agreed between experts and regulatory agencies. Moreover, the Company announced its active participation at the AASLD congress in San Francisco (Nov 13-17, 2015), where new data concerning both the GOLDEN-505 study and the Phase 3 of Elafibranor in NASH will be presented in multiple sessions.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT's lead proprietary compound, GFT505/Elafibranor, that has completed a positive Phase 2b study in NASH and is currently launching a Phase 3 study.

With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 90 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com

Disclaimer:

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on GENFIT's website (www.genfit.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country.

Contacts

GENFIT | Jean-François Mouney - CEO & Chairman of the Management Board | Ph. +333 2016 4000

MILESTONES – Relation Presse | Bruno Arabian | Ph. +331 8362 3484 / +336 8788 4726 – barabian@milestones.fr